Please turn JavaScript on
Find more feeds
BioPharmCatalyst icon

BioPharmCatalyst

Follow BioPharmCatalyst's news and updates in a matter of seconds! We will deliver any update via email, phone or you can read them from here on the site on your own news page.

You can even combine different feeds with the feed for BioPharmCatalyst.

Subscribing and unsubscribing is fast, easy and risk free.

The whole service is free of cost.

BioPharmCatalyst: Biotech Stocks for investors and traders • BioPharmCatalyst

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  0.72 / day

Message History

Biotech News October 22, 2026: MRNA -18% Phase 3 Melanoma Win; VCRE +11% Clears ASPIRE Futility Review
TL;DR — Biotech News: October 22, 2026 Moderna (MRNA): Phase 3 INTerpath-001 showed a 42% reduction in recurrence or death and 38% reduction in distant metastasis or death with intismeran autogene plus Keytruda. Vicore Pharma (VCRE): Phase 2b ASPIRE passed its planned futility analysis in 378 IPF patients, with no safety concerns and mid-2027 t...

Read full story
Biotech Movers October 21, 2026: PDS Biotech PDSB +29% on Board Refresh; Teknova TKNO -21% After $40M Offering
TL;DR — Biotech Movers: October 21, 2026 PDS Biotechnology (PDSB): Added three pharma veterans to its board as four directors departed, strengthening development, commercialization and partnership expertise. IMUNON (IMNN): Transferred ThermoDox to VoxelDox while retaining equity, milestones and royalties, allowing greater focus on Phase 3 OVATI...

Read full story
Biotech News October 20, 2026: EVAX +23% Reports Durable EVX-01 Benefit; BCDA +18% Advances Helix De Novo Review
TL;DR — Biotech Movers: October 20, 2026 Evaxion Biotech (EVAX): All six EVX-01 responders entering the third-year extension remained progression-free, reinforcing earlier Phase 2 melanoma results ahead of ESMO 2026. BioCardia (BCDA): FDA accepted the updated Helix catheter De Novo pre-submission, with substantive review and an agency meeting e...

Read full story
Biotech News October 19, 2026: SLN +126% to Be Acquired by Merck KGaA for $1.3B; MANE +12% Reports Positive Phase 3 Data
TL;DR — Biotech News: October 19, 2026 Silence Therapeutics (SLN): Merck KGaA agreed to acquire Silence for $20.00 per ADS, valuing the company at roughly $1.3B in equity and representing a 130% premium to its October 16 close. Veradermics (MANE): Phase 3 Study 304 met all primary and secondary efficacy endpoin...

Read full story
Biotech Movers October 16, 2026: MDXH -66% on Guidance Withdrawal; GUTS -63% After REMAIN-1 Data
TL;DR — Biotech Movers: October 16, 2026 MDxHealth (MDXH): Preliminary Q3 revenue was ~$22.7M and management withdrew $110M–$115M full-year guidance after sales-force attrition drove an 11% drop in tissue test volume. Fractyl Health (GUTS): REMAIN-1 met its 6-month co-primary endpoint, with 80% weight-loss retention versus 67% for sham; 12-mont...

Read full story